Skip to content
Get started
GLP1s

💉 Retatrutide: What We Know So Far About the Triple Agonist Weight-Loss Drug

Julie |

There’s been a lot of buzz recently about retatrutide — an investigational “triple agonist” peptide that’s shown remarkably large weight-loss effects in early trials.

Here’s TribElle’s clear, patient-friendly breakdown of:

  • What retatrutide is

  • What the latest evidence says

  • What it means for you

🧬 What is Retatrutide?

Retatrutide (also called LY-3437943) is an experimental, once-weekly injectable peptide being developed by Eli Lilly — the same company behind Mounjaro (tirzepatide).

It’s known as a triple agonist because it activates three different hormone receptors at once:

  • GIP (glucose-dependent insulinotropic polypeptide)

  • GLP-1 (glucagon-like peptide-1)

  • Glucagon receptor

By acting on all three pathways, retatrutide aims to:

  • Reduce appetite

  • Increase energy expenditure

  • Improve glucose and lipid metabolism

🧪 Source: Nature

📊 What Have the Trials Shown So Far?

Retatrutide has completed Phase 2 trials — and the numbers are attention-grabbing:

  • In a 48-week study, patients on higher doses lost on average 22–24% of their body weight

  • Even at 24 weeks, mean losses in the mid-teens (percentage) were reported

  • These results are larger than those typically seen with current GLP-1 drugs like Wegovy or Mounjaro

Beyond weight loss, studies have shown metabolic benefits, including:

  • Reduced liver fat

  • Improved lipid levels

  • Changes in body composition (fat mass loss)

But — and this matters — these are still mid-stage trial results. Phase 3 studies and longer-term safety monitoring are ongoing.

🧪 Sources: Nature, Lilly Investor Relations, The Lancet

⚠️ What About Side Effects?

So far, the side effect profile looks broadly similar to other incretin-based therapies, including:

  • Nausea

  • Vomiting

  • Diarrhoea

  • Constipation

Most are mild-to-moderate and occur during dose escalation.

Because retatrutide also activates the glucagon receptor, researchers are closely watching for:

  • Changes in glucose handling

  • Shifts in energy metabolism

For now, no unexpected safety concerns have emerged — but longer-term safety data is not yet available.

🧪 Sources: PMC, ScienceDirect

🔁 How Does Retatrutide Compare to Semaglutide and Tirzepatide?

There are no direct head-to-head trials yet, but early signals suggest:

  • Retatrutide’s higher-dose regimens may lead to greater weight loss than semaglutide or tirzepatide

  • However, indirect comparisons have limitations:

    • Different study designs

    • Different populations

    • Different durations

Bottom line: we’ll need Phase 3 comparisons and real-world data to truly know how it stacks up.

🧪 Sources: PMC, Lilly Investor Relations

📅 Regulatory Status — Is It Available Yet?

Not yet.

Retatrutide is:

  • ✅ In Phase 3 clinical trials

  • ❌ Not yet approved by any regulatory agency

  • 🚫 Not available for routine prescription or sale

🧪 Source: ClinicalTrials

💬 What This Means for TribElle Patients

If you're currently using a licensed GLP-1 or GLP/GIP medication for weight management or diabetes, retatrutide is exciting — but not relevant to your treatment just yet.

Here’s why:

  • It’s not yet approved

  • It lacks long-term safety data

  • And it’s only available in clinical trials

Yes, the trial data is promising. But real-world results, rare risks, and pricing access are still unknown.

👩‍⚕️ Curious About What’s Next?

If you’re interested in newer therapies or research trials:

  • Speak to your TribElle prescriber

  • They can tell you if trials are recruiting and whether participation would suit your medical history

  • They’ll also help you navigate future options as more medications become available

🔎 Bottom Line

Retatrutide is one of the most exciting developments in GLP-1 science right now. A triple agonist that’s shown large weight-loss effects and promising metabolic improvements in early trials.

But it’s still experimental.

Until long-term phase 3 data confirms safety and effectiveness, licensed therapies — paired with expert support — remain the best option.

That’s what we’re here for.

📚 Want to Read the Research?

Share this post

Keep reading